Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
% Protection
7%
Adjuvanted
14%
Aluminum Hydroxide
7%
Antibody Response
100%
Antibody Targeting
7%
Antibody-dependent Cellular Cytotoxicity
35%
As(V)
7%
Clinical Efficacy
7%
Correlates of Protection
7%
D-protein
21%
Defective Virus
7%
Efficacy Trial
7%
Escalating Dose
7%
Experimental Vaccines
7%
Fc Receptor
7%
Global Health Challenges
7%
Glycoprotein D
100%
Herpes Simplex Virus
100%
Herpes Simplex Virus 2 (HSV-2)
14%
Herpes Simplex Virus Type 1 (HSV-1)
7%
High Titer
7%
Immunization Programs
7%
Immunogenicity
7%
Intradermal Administration
7%
Intradermal Immunization
7%
Intradermal Route
7%
Intramuscular Administration
7%
Intramuscular Route
7%
Intramuscularly
7%
Latency
7%
Lethal Infection
7%
Mucosal Disease
7%
Neurological Diseases
7%
Neutralizing Antibodies
21%
Neutralizing Response
7%
Partial Protection
7%
Phosphoinositide Lipid
7%
Protective Antibodies
100%
Protein Vaccine
7%
Recombinant Glycoprotein
7%
Replication-defective
7%
Route of Administration
7%
Subcutaneous Route
7%
Vaccination Route
100%
Vaccine Effectiveness
7%
Viral Replication
7%
Virus Challenge
7%
Virus-neutralizing Antibodies
7%
Immunology and Microbiology
Adjuvant
7%
Antibody Response
100%
Antibody-Dependent Cell-Mediated Cytotoxicity
35%
Defective Interfering Particle
7%
Fc Receptor
7%
Global Health
7%
Glycoprotein
100%
Herpes Simplex Virus
100%
Herpes Simplex Virus 2
14%
Human Alphaherpesvirus 1
7%
Immunogenicity
7%
Low Drug Dose
14%
Neutralizing Antibody
21%
Phosphoryl Lipid A
7%
Preclinical Study
7%
Replication
7%
Titer
7%
Vaccine Efficacy
7%
Viral Replication
7%
Virus Antibody
7%